SAFEALLOSHEET: Phase I Trial of Allogeneic Keratinocyte Sheets for Burn Wounds

A 6-month follow-up study of five patients with 20–50% total body surface area burns, evaluating the safety and feasibility of allogeneic cultured keratinocyte sheets. The dataset includes clinical outcomes, scar quality assessments, and histopathology results from a phase I trial. It was authored by Shayan Farzanbakhsh and published on figshare under a CC-BY-4.0 license.

Use Cases

• Assessing safety and feasibility of allogeneic cell therapies based on reported adverse event rates and graft take outcomes.
• Modeling wound closure time based on the reported 1-3 month healing periods for different patients.
• Analyzing scar quality improvement based on Vancouver Scar Scale (VSS) and Patient and Observer Scar Assessment Scale (POSAS) scores provided in the description.

Strengths

• Includes specific clinical metrics such as POSAS patient scores (28.4 ± 9.8 to 19.2 ± 6.0) and VSS scores (5.0 ± 2.1 to 3.6 ± 2.4) over a 6-month follow-up.
• Reports results from a defined patient cohort of five individuals with 20–50% total body surface area burns.
• Contains histopathology data from baseline and 6-month time points, confirming epithelialization.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect geographic/temporal bias inherent to the single clinical trial source.

Provenance

Source

figshare, author Shayan Farzanbakhsh

Collection Method

Data likely originates from a single-arm, phase I clinical trial (SAFEALLOSHEET) registered with the Iranian Registry of Clinical Trials.

Time Range

Study follow-up period was 6 months; specific trial dates are not provided.

Freshness

Last updated 2026-04-20 09:20:13; freshness should be verified.